Sign In
Buy URGN
$26.60
+0.0600 (+0.226%)
At Close: Jun 03, 2026
Bronstein, Gewirtz & Grossman, LLC Is Investigating UroGen Pharma Ltd. (URGN) And Encourages Investors to Connect
10:00am, Wednesday, 28'th May 2025
NEW YORK CITY, NY / ACCESS Newswire / May 28, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of UroGen Pharma Ltd. ("UroGen" or "the Company") (NAS
Did UroGen Pharma Ltd. (URGN) Mislead Investors?
09:15am, Wednesday, 28'th May 2025
NEW YORK, NY / ACCESS Newswire / May 28, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of UroGen Pharma Ltd. ("UroGen Pharma Ltd.
UroGen Pharma to Present at TD Cowen: 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA
04:00pm, Tuesday, 27'th May 2025
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod
Investigation Alert: UroGen Pharma Ltd. (URGN) Under Scrutiny - Contact Levi & Korsinsky for Details
03:30pm, Tuesday, 27'th May 2025
NEW YORK, NY / ACCESS Newswire / May 27, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of UroGen Pharma Ltd. ("UroGen Pharma Ltd.
UroGen Pharma Ltd. (URGN) Shares Crash Again Amid FDA's ODAC Vote Against UGN-102, Company Facing Investor Scrutiny – Hagens Berman
03:14pm, Tuesday, 27'th May 2025
SAN FRANCISCO, May 27, 2025 (GLOBE NEWSWIRE) -- On May 21, 2025, investors in UroGen Pharma Ltd. (NASDAQ: URGN) saw the price of their shares crash 44% after the company announced that the FDA's Oncol
Did You Suffer Losses in UroGen Pharma Ltd. (URGN)? Contact Levi & Korsinsky About Securities Fraud Claims
12:00pm, Tuesday, 27'th May 2025
NEW YORK, NY / ACCESS Newswire / May 27, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of UroGen Pharma Ltd. ("UroGen Pharma Ltd.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN
11:50am, Tuesday, 27'th May 2025
NEW YORK CITY, NY / ACCESS Newswire / May 27, 2025 / Pomerantz LLP is investigating claims on behalf of investors of UroGen Pharma Ltd. ("UroGen" or the "Company") (NASDAQ:URGN).
Lost Money on UroGen Pharma Ltd. (URGN)? Contact Levi & Korsinsky to Protect Your Rights
10:15am, Tuesday, 27'th May 2025
NEW YORK, NY / ACCESS Newswire / May 27, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of UroGen Pharma Ltd. ("UroGen Pharma Ltd.
Bronstein, Gewirtz & Grossman, LLC Encourages UroGen Pharma Ltd. (URGN) Stockholders to Inquire about Securities Investigation
10:00am, Tuesday, 27'th May 2025
NEW YORK CITY, NY / ACCESS Newswire / May 27, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of UroGen Pharma Ltd. ("UroGen" or "the Company") (NAS
ATTENTION UroGen Pharma Ltd. (URGN) Investors: Possible Fraud - Contact Levi & Korsinsky Today
11:30am, Monday, 26'th May 2025
NEW YORK, NY / ACCESS Newswire / May 26, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of UroGen Pharma Ltd. ("UroGen Pharma Ltd.
NEW YORK CITY, NY / ACCESS Newswire / May 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of UroGen Pharma Ltd. ("UroGen" or "the Company") (NAS
UroGen Pharma Stock Receives Downgrade As Analyst Cites FDA Panel Setback For Key Bladder Cancer Drug
02:16pm, Sunday, 25'th May 2025
HC Wainwright & Co. analyst Raghuram Selvaraju downgraded the rating on UroGen Pharma Ltd. URGN from Buy to Neutral.
Investors in UroGen Pharma Ltd. (URGN) Warned of Potential Securities Fraud- Contact Levi & Korsinsky Today
11:00am, Sunday, 25'th May 2025
NEW YORK, NY / ACCESS Newswire / May 25, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of UroGen Pharma Ltd. ("UroGen Pharma Ltd.
NEW YORK CITY, NY / ACCESS Newswire / May 25, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of UroGen Pharma Ltd. ("UroGen" or "the Company") (NAS
Ongoing Investigation: UroGen Pharma Ltd. (URGN) May Have Misled Shareholders - Levi & Korsinsky Investigates
06:01pm, Saturday, 24'th May 2025
NEW YORK, NY / ACCESS Newswire / May 24, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of UroGen Pharma Ltd. ("UroGen Pharma Ltd.
